Literature DB >> 11222360

How I treat chronic graft-versus-host disease.

G B Vogelsang1.   

Abstract

Allogeneic stem cell transplantation (SCT) is now a commonplace procedure. Clinicians who care for patients with hematologic malignancies and aplastic anemia are almost certain to follow up patients after SCT. This review is intended to help clinicians observe patients for probably the most important late complication of SCT, chronic graft-versus-host disease (GVHD). It reviews the pathophysiology, risk factors, clinical manifestations, evaluation, treatment, and supportive care of chronic GVHD.

Entities:  

Mesh：

Year:  2001        PMID： 11222360     DOI： 10.1182/blood.v97.5.1196

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  35 in total

Review 1.  How we treat chronic graft-versus-host disease.

Authors:  Mary E D Flowers; Paul J Martin
Journal:  Blood       Date:  2014-11-14       Impact factor: 22.113

2.  [Graft-versus-Host Disease (GvHD) - an update : Part 1: Pathophysiology, clinical features and classification of GvHD].

Authors:  R Travnik; M Beckers; D Wolff; E Holler; M Landthaler; S Karrer
Journal:  Hautarzt       Date:  2011-02       Impact factor: 0.751

3.  [Cutaneous graft-versus-host disease].

Authors:  S Karrer
Journal:  Hautarzt       Date:  2003-05       Impact factor: 0.751

Review 4.  Cutaneous graft-versus-host disease--clinical considerations and management.

Authors:  Peggy A Wu; Edward W Cowen
Journal:  Curr Probl Dermatol       Date:  2012-02-17

5.  Graft-versus-host disease therapy: something else beyond glucocorticoids?

Authors:  Carmen Martínez; Alvaro Urbano-Ispízua
Journal:  Haematologica       Date:  2011-09       Impact factor: 9.941

6.  Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation.

Authors:  Steven Z Pavletic; Shelly L Carter; Nancy A Kernan; Jean Henslee-Downey; Adam M Mendizabal; Esperanza Papadopoulos; Roger Gingrich; James Casper; Saul Yanovich; Daniel Weisdorf
Journal:  Blood       Date:  2005-07-26       Impact factor: 22.113

7.  EBMT risk score can predict the outcome of leukaemia after unmanipulated haploidentical blood and marrow transplantation.

Authors:  H-T Wang; Y-J Chang; L-P Xu; D-H Liu; Y Wang; K-Y Liu; X-J Huang
Journal:  Bone Marrow Transplant       Date:  2014-04-28       Impact factor: 5.483

Review 8.  Principles and overview of allogeneic hematopoietic stem cell transplantation.

Authors:  Sergio Giralt; Michael R Bishop
Journal:  Cancer Treat Res       Date:  2009

9.  Prospective predictors of return to work in the 5 years after hematopoietic cell transplantation.

Authors:  Anne C Kirchhoff; Wendy Leisenring; Karen L Syrjala
Journal:  J Cancer Surviv       Date:  2010-03       Impact factor: 4.442

10.  Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.

Authors:  Paul J Martin; Barry E Storer; Scott D Rowley; Mary E D Flowers; Stephanie J Lee; Paul A Carpenter; John R Wingard; Paul J Shaughnessy; Marcel P DeVetten; Madan Jagasia; Joseph W Fay; Koen van Besien; Vikas Gupta; Carrie Kitko; Laura J Johnston; Richard T Maziarz; Mukta Arora; Pamala A Jacobson; Daniel Weisdorf
Journal:  Blood       Date:  2009-03-06       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.